Viewing data from:

DIFLUCAN

NDA

FLUCONAZOLE | N019949 | PFIZER CENTRAL RESEARCH

4 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Diflucan (2023)

Total Spending

$229K

Total Claims

483

Beneficiaries

279

Avg Cost/Unit

$36.89

Spending Trend

$769K(2019)→$544K(2020)→$539K(2021)→$322K(2022)→$229K(2023)

YoY Change:-21.0%

5yr CAGR:-8.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain15 active DMFs13 inactive

14 active API suppliers hold Drug Master Files for this ingredient.

QUIMICA SINTETICA SAFLUCONAZOLE

DMF 89751991

INKE SAFLUCONAZOLE

DMF 147141999

MATRIX PHARMACORP PRIVATE LTDFLUCONAZOLE USP

DMF 150452000

CIPLA LTDFLUCONAZOLE USP

DMF 151612000

TARO PHARMACEUTICAL INDUSTRIES LTDFLUCONAZOLE USP

DMF 158222002

ZYDUS LIFESCIENCES LTDFLUCONAZOLE USP

DMF 162972002

DR REDDYS LABORATORIES LTDFLUCONAZOLE (FORM-2)

DMF 163162003

APITORIA PHARMA PRIVATE LTDFLUCONAZOLE USP

DMF 181762005

ALIVUS LIFE SCIENCES LTDFLUCONAZOLE USP

DMF 207342007

VIRUPAKSHA ORGANICS LTDFLUCONAZOLE USP

DMF 244372010

HENAN PURUI PHARMACEUTICAL CO LTDFLUCONAZOLE

DMF 374202022

SYNERGENE ACTIVE INGREDIENTS PRIVATE LTDFLUCONAZOLE USP

DMF 377032023

APITORIA PHARMA PRIVATE LTDFLUCONAZOLE USP (CIP PROCESS)

DMF 398762024

ATUL BIOSCIENCE LTDFLUCONAZOLE

DMF 404262024

ENDOC LIFECARE PVT LTDFLUCONAZOLE USP

DMF 424882025

CIPLA LTDInactiveFLUCONAZOLE USP

DMF 115241995

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDInactiveFLUCONAZOLE

DMF 144191999

WOCKHARDT LTDInactiveFLUCONAZOLE

DMF 148632000

GEDEON RICHTER LTDInactiveFLUCONAZOLE

DMF 158832002

CADILA PHARMACEUTICALS LTDInactiveFLUCONAZOLE

DMF 163912002

SIGNA SA DE CVInactiveFLUCONAZOLE

DMF 164202003

FDC LTDInactiveFLUCONAZOLE

DMF 166322003

GLENMARK GENERICS LTDInactiveFLUCONAZOLE

DMF 170972004

APOTECNIA SAInactiveFLUCONAZOLE

DMF 172942004

IPCA LABORATORIES LTDInactiveFLUCONAZOLE USP

DMF 209292007

GRANULES INDIA LTDInactiveFLUCONAZOLE USP

DMF 227102009

POLYDRUG LABORATORIES PVT LTDInactiveFLUCONAZOLE

DMF 234052009

IPCA LABORATORIES LTDInactiveFLUCONAZOLE USP (G3 PROCESS)

DMF 247682011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

23 letters from Drugs@FDA

Date	Submission	Document
Feb 13, 2024	SUPPL -72	View Letter (PDF)
Jul 13, 2023	SUPPL -74	View Letter (PDF)
Jan 18, 2023	SUPPL -73	View Letter (PDF)
Mar 10, 2022	SUPPL -71	View Letter (PDF)
Oct 27, 2021	SUPPL -70	View Letter (PDF)
Sep 9, 2020	SUPPL -69	View Letter (PDF)
Feb 20, 2019	SUPPL -65	View Letter (PDF)
Mar 15, 2018	SUPPL -64	View Letter (PDF)
Jan 26, 2018	SUPPL -68	View Letter (PDF)
Oct 31, 2017	SUPPL -67	View Letter (PDF)
Oct 31, 2014	SUPPL -60	View Letter (PDF)
Mar 25, 2014	SUPPL -58	View Letter (PDF)
Sep 17, 2013	SUPPL -57	View Letter (PDF)
Nov 21, 2011	SUPPL -55	View Letter (PDF)
Jun 8, 2011	SUPPL -51	View Letter (PDF)
Apr 29, 2011	SUPPL -52	View Letter (PDF)
Aug 10, 2010	SUPPL -48	View Letter (PDF)
Apr 4, 2008	SUPPL -41	View Letter (PDF)
Oct 8, 2004	SUPPL -35	View Letter (PDF)
Oct 8, 2004	SUPPL -32	View Letter (PDF)
Oct 8, 2004	SUPPL -30	View Letter (PDF)
Mar 28, 2004	SUPPL -37	View Letter (PDF)
Aug 7, 2002	SUPPL -33	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 50MG

RLDAB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 29, 1990

No patent or exclusivity listings for this strength.

#002 — 100MG

RLDAB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 29, 1990

#003 — 200MG

RLDAB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 29, 1990

#004 — 150MG

RLDAB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 30, 1994